Stay updated with breaking news from Primary Analysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Four studies being presented during the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition point to the transformative...
Updated results from the MRD cohort of the Phase 2 CAPTIVATE study also highlight potential for treatment-free remissions with IMBRUVICA® plus venetoclax in an oral presentation at ASH... | December 11, 2021
/PRNewswire/ -- Four studies being presented during the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition point to the transformative...
Complete and overall response rates and durability of response were well maintained across majority of high-risk subgroups with a significant unmet need1 Median follow-up of approximately 17 months
/PRNewswire/ -- Novartis announced Kymriah® (tisagenlecleucel) demonstrated strong efficacy in high-risk patients with relapsed or refractory (r/r) follicular...